Effectiveness of treatment with biologic- and disease-modifying antirheumatic drugs in rheumatoid arthritis patients in Colombia
- 30 May 2016
- journal article
- research article
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 70 (6) , 506-511
Abstract
Rheumatoid arthritis (RA) is an autoimmune disease cause of disability and high costs. To determine the effectiveness of therapy with biologic- and disease-modifying antirheumatic drugs (DMARDs) in patients with RA and factors associated with the control of the disease. Retrospective cohort study of RA patients receiving treatment with DMARDs in a rheumatologic healthcare institution in five Colombian cities from December 2009 to August 2013. The effectiveness was assessed by Disease Activity Score-28 (DAS-28) and a lower value of 2.6 was considered remission. A total of 827 patients were studied for an average observation period of 17.3 ± 11.0 months, with mean age 54.3 ± 13.1 years. The most frequently used DMARDs were methotrexate, leflunomide and chloroquine. The most frequently used biological DMARDs were etanercept and abatacept. Initially, 17.8% of the patients received some biological DMARDs in comparison with 28.7% at the end of the observation period. A median DAS28 of 3.5 was found, which was reduced by the end of the observation period to 2.8 (p < 0.001), and cases of patients who were in remission increased from 30.1% to 42.9%. Treatment with leflunomide (OR: 0.47; CI 95%: 0.35-0.64, p < 0.001) or rituximab (OR: 0.37; CI 95%: 0.17-0.83, p = 0.016) was associated with a lesser probability of reaching remission. To be treated in the city of Manizales (OR: 2.56; CI 95%: 1.36-4.82, p = 0.004) was associated with a high probability of remission. Biological and DMARDs therapy for RA was effective in a relevant proportion of Colombian patients as a consequence of management with strategies set on remission aims quantified using DAS28. Cost-effectiveness of the therapy must be evaluated.Keywords
Funding Information
- Universidad Tecnológica de Pereira
- Audifarma S.A.
- Pfizer Colombia
This publication has 19 references indexed in Scilit:
- Comparative Efficacy of Novel DMARDs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with Inadequate Response to Conventional DMARDs: A Network Meta-AnalysisJournal of Managed Care & Specialty Pharmacy, 2015
- Daily practice feasibility and effectiveness of treating long-standing rheumatoid arthritis to target with synthetic disease-modifying antirheumatic drugs: a prospective cohort studyClinical Rheumatology, 2015
- Treatment of rheumatoid arthritis with methotrexate alone and in combination with other conventional DMARDs using the T2T strategy. A cohort studyClinical Rheumatology, 2014
- Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survivalSeminars in Arthritis and Rheumatism, 2014
- Optimizing treatment strategies in early RANature Reviews Rheumatology, 2013
- Estrategia «treat to target» en la artritis reumatoide: beneficios realesReumatología Clínica, 2013
- Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritisRheumatology, 2012
- Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practiceArthritis Care & Research, 2012
- Implementation of a treat-to-target strategy in very early rheumatoid arthritis: Results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort studyArthritis & Rheumatism, 2011
- Rheumatoid arthritisThe Lancet, 2010